160 related articles for article (PubMed ID: 37231169)
1. Does insulin make breast cancer cells resistant to doxorubicin toxicity?
Lykhova O; Zavelevich M; Philchenkov A; Vidasov N; Kozak T; Lozovska Y; Andrusyshyna I; Bishayee A; Borikun T; Lukianova N; Chekhun V
Naunyn Schmiedebergs Arch Pharmacol; 2023 Nov; 396(11):3111-3122. PubMed ID: 37231169
[TBL] [Abstract][Full Text] [Related]
2. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics.
Chekhun VF; Borikun TV; Lukianova NY
Exp Oncol; 2016 Mar; 38(1):26-30. PubMed ID: 27031715
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells.
Sun FD; Wang PC; Luan RL; Zou SH; Du X
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1342-1350. PubMed ID: 29565492
[TBL] [Abstract][Full Text] [Related]
4. miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A.
Zhang Y; He Y; Lu LL; Zhou ZY; Wan NB; Li GP; He X; Deng HW
Kaohsiung J Med Sci; 2019 Jan; 35(1):17-23. PubMed ID: 30844143
[TBL] [Abstract][Full Text] [Related]
5. Artemisinin modulating effect on human breast cancer cell lines with different sensitivity to cytostatics.
Chekhun VF; Lukianova NY; Borikun TV; Zadvorny TV; Mokhir A
Exp Oncol; 2017 Mar; 39(1):25-29. PubMed ID: 28361857
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-222 promotes drug resistance to doxorubicin in breast cancer via regulation of miR-222/bim pathway.
Dai H; Xu LY; Qian Q; Zhu QW; Chen WX
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31273056
[TBL] [Abstract][Full Text] [Related]
7. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
[TBL] [Abstract][Full Text] [Related]
8. Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells.
Hu D; Li M; Su J; Miao K; Qiu X
Genet Test Mol Biomarkers; 2019 Mar; 23(3):156-165. PubMed ID: 30807260
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin resistance in breast cancer xenografts and cell lines can be counterweighted by microRNA-140-3p, through PD-L1 suppression.
Zhang X; Wang C; Huang C; Yang J; Wang J
Histol Histopathol; 2023 Oct; 38(10):1193-1204. PubMed ID: 36621840
[TBL] [Abstract][Full Text] [Related]
10. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
11. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
12. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
13. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
14. Apigenin alleviates resistance to doxorubicin in breast cancer cells by acting on the JAK/STAT signaling pathway.
Maashi MS; Al-Mualm M; Al-Awsi GRL; Opulencia MJC; Al-Gazally ME; Abdullaev B; Abdelbasset WK; Ansari MJ; Jalil AT; Alsaikhan F; Shalaby MN; Mustafa YF
Mol Biol Rep; 2022 Sep; 49(9):8777-8784. PubMed ID: 35804214
[TBL] [Abstract][Full Text] [Related]
15. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
[TBL] [Abstract][Full Text] [Related]
16. METTL3-mediated m
Zhou Z; Cao Y; Yang Y; Wang S; Chen F
Epigenetics; 2023 Dec; 18(1):2217033. PubMed ID: 37243702
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
[TBL] [Abstract][Full Text] [Related]
18. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
19. MiR-133a Is Functionally Involved in Doxorubicin-Resistance in Breast Cancer Cells MCF-7 via Its Regulation of the Expression of Uncoupling Protein 2.
Yuan Y; Yao YF; Hu SN; Gao J; Zhang LL
PLoS One; 2015; 10(6):e0129843. PubMed ID: 26107945
[TBL] [Abstract][Full Text] [Related]
20. ATP-dependent activity and mitochondrial localization of drug efflux pumps in doxorubicin-resistant breast cancer cells.
Dartier J; Lemaitre E; Chourpa I; Goupille C; Servais S; Chevalier S; Mahéo K; Dumas JF
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):1075-1084. PubMed ID: 28214549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
